Recent Trends of Helicobacter pylori Eradication Therapy in Korea.
10.7704/kjhugr.2012.12.4.219
- Author:
Yun Kyeong KIM
1
;
Joon Sung KIM
;
Byung Wook KIM
Author Information
1. Division of Gastroenterology, Incheon St. Mary's Hospital, Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Incheon, Korea. gastro@catholic.ac.kr
- Publication Type:Review
- Keywords:
Helicobacter pylori;
Eradication
- MeSH:
Adenocarcinoma;
Anti-Bacterial Agents;
Bismuth;
Communicable Diseases;
Gastritis;
Helicobacter;
Helicobacter pylori;
Korea;
Lymphoid Tissue;
Lymphoma, B-Cell, Marginal Zone;
Peptic Ulcer
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2012;12(4):219-223
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Helicobacter pylori infection is one of the most common gastrointestinal infectious diseases in Korea and is related to diseases such as gastritis, peptic ulcer disease, marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type, and gastric adenocarcinoma. The eradication of H. pylori infection requires combinations of antibiotics and acid suppressants. Triple therapy has been considered as the first-line therapy for a long time. However, its eradication rate is declining and we need more effective strategies. Quadruple therapy including acid suppressants, bismuth, and other two antibiotics is a main rescue therapy after first-line therapy failure in Korea. In this review, we describe new therapeutic regimens and new trends of H. pylori eradication in Korea.
